Biotech Bearish Stocks: Celldex Therapeutics (NASDAQ:CLDX), Dyax Corp. (NASDAQ:DYAX), Lexicon Pharmaceuticals (NASDAQ:LXRX), Arrowhead Research (NASDAQ:ARWR)

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that final data from its Phase 1 study of CDX-1401 in solid tumors, including long-term patient follow-up, have been published in Science Translational Medicine (Vol 6 Issue 232). The data demonstrate robust antibody and T cell responses and evidence of clinical benefit in patients with very advanced cancers and suggest that CDX-1401 may predispose patients to better outcomes on subsequent therapy with checkpoint inhibitors. Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares after opening at $15.93 moved to $15.99 on last trade day and at the end of the day closed at $14.71 . Company price to sales ratio in past twelve months was calculated as 320.61 and price to cash ratio as 4.34. Celldex Therapeutics, Inc. (NASDAQ:CLDX) showed a positive weekly performance of 7.14%.

Dyax Corp. (NASDAQ:DYAX) will host a webcast and conference call, including an open question and answer session, Wednesday, April 30, 2014. Dyax Corp. (NASDAQ:DYAX) shares fell -5.91% in last trading session and ended the day on $6.84. DYAX return on equity ratio is recorded as 101.70% and its return on assets is -34.40%. Dyax Corp. (NASDAQ:DYAX) yearly performance is 61.70%.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) surged 5.16% after the company reported positive results in a clinical trial of type 1 diabetes drug LX4211. The trial found that the drug successfully reduced insulin use and improved glycemic control in patients with poorly controlled diabetes. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares moved down -8.57% in last trading session and was closed at $1.60 while trading in range of $1.58 – $1.74 – Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) year to date (YTD) performance is -11.11%.

Arrowhead Research Corporation (NASDAQ:ARWR) announced that the first cohort of 8 patients has been fully enrolled and dosed in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The trial remains on schedule to meet the previously stated goal of completing dosing in the second quarter and releasing top line results in the third quarter. Arrowhead Research Corp (NASDAQ:ARWR) weekly performance is 12.17%. On last trading day company shares ended up $12.81. Arrowhead Research Corp (NASDAQ:ARWR) distance from 50-day simple moving average (SMA50) is -33.56%. Analysts mean target price for the company is $28.75.